Clinical trials

3

Search and review clinical trials. Use filters to narrow results by trial status, phase, treatment, biological sex and sponsor.

Condition / disease
Location
Status: Not yet recruiting

Perirenal Adipose Tissue Modification Therapy for Resistant Hypertension

The goal of this clinical trial is to investigate if focused power ultrasound (FPU) targeted perirenal adipose tissue modification therapy would be effective and safe in treating resistant hypertension. The primary outcome of the study is the difference in the reduction of 24h mean systolic blood pressure between treatment and sham procedure groups 6 months after treatment. The secondary outcomes include the reduction of clinic blood pressure 1, 3, and 6 months after treatment, the reduction of 24h mean blood pressure 1, 3, and 6 months after treatment, and the drug burden of antihypertensive treatment. The safety evaluation includes the incidence of all-cause death, cardiovascular events (stroke and myocardial infarction), renal failure, and other adverse events.

Participants needed: 220
Trial details
Phase: Phase 3Age: 18-75Biological sex: AllType: InterventionalSponsor: Yan LiUpdated: Nov 18, 2025Locations: 1
Eligibility criteria

Male or female participants aged 18-75 years old; [+4]

Secondary hypertension; [+10]

Status: Recruiting

Morning Versus Bedtime Dosing of Antihypertensive Medication

Previous studies have shown that elevated nighttime blood pressure (BP) was more closely associated with cardiovascular mortality and morbidity than daytime and clinic BPs. With increasingly advanced technology, not only 24-hour ambulatory but also home BP monitors can be used to evaluate nighttime BP. The validation study of the Omron HEM 9601T showed that the wrist-type home BP monitor could be a suitable and reliable tool for the diagnosis and management of nocturnal hypertension. However, up to now, there is no data on home nighttime BP in Chinese patients and it is unclear if different dosing time would reduce ambulatory and home nighttime BPs differently. The investigators therefore designed a multicenter randomized clinical trial to compare between morning dosing and bedtime dosing of antihypertensive medications in the difference in nighttime, daytime and the 24-h BP reductions evaluated by both ambulatory and home BP monitoring, and in target organ protections.

Participants needed: 300
Trial details
Phase: Phase 4Age: 18-70Biological sex: AllType: InterventionalSponsor: Yan LiUpdated: Jan 6, 2025Locations: 1
Eligibility criteria

Male or female patients aged 18-70 years old; [+5]

Secondary hypertension; [+10]

Status: Recruiting

A Registry Study on the "Action of Controlling Ambulatory Blood Pressure to Target in Ten Thousand Patients"

24 hour ambulatory blood pressure (ABP) monitoring should be the first choice for diagnosis and treatment of hypertension according to European Societyof Hypertension (ESH) and the European Society of Cardiology (ESC) guideline on ambulatory blood pressure monitoring. Finally, we should promote the clinical application of 24 hour ambulatory blood pressure monitoring to greatly improve the management level of hypertension in China and effectively reduce the risk caused by hypertension in the population. Information of hypertensive patients with ambulatory blood pressure monitoring was prospectively registered nationwide,and then to investigate whether there was difference in cardiovascular prognosis according to the control of ABP.

Participants needed: 10,000
Trial details
Age: 18-80Biological sex: AllType: ObservationalSponsor: Yan LiUpdated: Jan 6, 2025Locations: 1
Eligibility criteria

Age 18-80 years old [+4]

Without antihypertensive drug use [+2]